共 50 条
- [1] Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Final analysis of the prospective, observational REFINE studyANNALS OF ONCOLOGY, 2022, 33 : S1459 - S1460Kim, Y. J.Kurosaki, M.Numata, K.Lim, H. Y.Ikeda, M.Kudo, M.Huang, Y-H.Shao, G.Kato, N.Kim, D-Y.Cho, S-B.Hsu, C-H.Lin, S-M.Jeng, L-B.Kuo, K-K.Mao, Y.Chewaskulyong, B.Khan, J.Ozgurdal, K.Qin, S.
- [2] Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 518 - 518Finn, Richard S.Merle, PhilippeIkeda, MasafumiKlumpen, Heinz-JosefMasi, GianlucaGranito, AlessandroLim, Ho YeongKudo, MasatoshiQin, ShukuiGerolami, ReneHuang, Yi-HsiangKim, Do YoungPinter, MatthiasKato, NaoyaKurosaki, MasayukiNumata, KazushiKhan, JaveedOzgurdal, KirhanKim, Yoon Jun
- [3] Regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world (RW) practice: Final analysis of the prospective, observational REFINE study by prior liver transplantation (PLT)ANNALS OF ONCOLOGY, 2023, 34 : S611 - S611Pinter, M.Kim, Y. J.Merle, P.Finn, R. S.Khan, J.Ozgurdal, K.Qin, S.
- [4] Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Interim results from the observational REFINE studyANNALS OF ONCOLOGY, 2020, 31 : S1306 - S1307Lim, H. Y.Kim, Y. J.Huang, Y-H.Shao, G.Kim, D. Y.Cho, S. B.Hsu, C-H.Lin, S-M.Jeng, L-B.Kuo, K-K.Mao, Y.Zhu, K.Hong, Y. M.Lee, H. C.Ryoo, B-Y.Niu, Z.Wu, L.Fiala-Buskies, S.Kapur, S.Qin, S.
- [5] Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Interim results from the observational REFINE studyANNALS OF ONCOLOGY, 2020, 31 : S699 - S699Lim, H. Y.Kim, Y. J.Huang, Y-H.Shao, G.Kim, D. Y.Cho, S. B.Hsu, C-H.Lin, S-M.Jeng, L-B.Kuo, K-K.Mao, Y.Zhu, K.Hong, Y. M.Lee, H. C.Ryoo, B-Y.Niu, Z.Wu, L.Fiala-Buskies, S.Kapur, S.Qin, S.
- [6] Real-world dosing of regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Interim analysis (IA) of the observational REFINE studyANNALS OF ONCOLOGY, 2020, 31 : S699 - S700Merle, P.Lim, H. Y.Finn, R. S.Ikeda, M.Kudo, M.Frenette, C.Masi, G.Kim, Y. J.Gerolami, R.Kurosaki, M.Numata, K.Klumpen, H-J.Zebger-Gong, H.Fiala-Buskies, S.Ozgurdal, K.Qin, S.
- [7] Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Interim analysis of the prospective, observational REFINE trialJOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)Lim, Ho YeongMerle, PhilippeFinn, Richard S.Frenette, CatherineMasi, GianlucaIkeda, MasafumiZebger-Gong, HongFiala-Buskies, SabineOzgurdal, KirhanKudo, MasatoshiQin, Shukui
- [8] Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE studyJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)Finn, Richard S.Kudo, MasatoshiKlumpen, Heinz-JosefLim, Ho YeongMerle, PhilippeIkeda, MasafumiMasi, GianlucaFrenette, Catherine T.Kim, Yoon JunGerolami, ReneKurosaki, MasayukiNumata, KazushiPisarenko, JuliaOzgurdal, KirhanQin, Shukui
- [9] Analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) and Child-Pugh (CP)-B liver function treated with regorafenib in routine clinical practice in the observational REFINE studyJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 452 - 452Kim, Yoon JunMerle, PhilippeFinn, Richard S.Kudo, MasatoshiKlumpen, Heinz-JosefLim, Ho YeongPinter, MatthiasBabajanyan, SvetlanaKhan, JaveedAwan, MariaOzgurdal, KirhanQin, Shukui
- [10] Contemporary real-world evidence in unresectable HCC (uHCC) patients treated with regorafenib in Taiwan: Interim results from the observational REFINE studyJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)Lin, Shi-MingHsu, Chih-HungJeng, Long-BinLin, Yih-JyhLee, Ming-YangLee, Teng-YuHuang, Yi-Hsiang